Addex's Spin-Out Neurosterix Initiates Phase 1 Study of NTX-253 for Schizophrenia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Globenewswire
- Clinical Trial Launch: Addex Therapeutics' spin-out Neurosterix has initiated a Phase 1 clinical study of NTX-253, aimed at evaluating its safety and tolerability in healthy volunteers, marking a significant advancement in the treatment of schizophrenia.
- Funding Background: Neurosterix was spun out from Addex in April 2024, raising $65 million in Series A financing, demonstrating strong market interest in its novel small molecule allosteric modulators and enhancing its research capabilities.
- Innovative Therapy Potential: NTX-253, as a selective positive allosteric modulator of the M4 receptor, may offer a differentiated efficacy and safety profile compared to traditional dopamine antagonists, indicating a new direction in schizophrenia treatment.
- Market Outlook: By selectively modulating the M4 receptor, NTX-253 is expected to reduce psychotic symptoms while avoiding the side effects associated with traditional medications, potentially securing a significant position in the schizophrenia treatment market.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
